Nebenwirkungen · Scemblix
Scemblix 20 mg film-coated tablets Scemblix 40 mg film-coated tablets Scemblix 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-148121 · Präparat HOS-099834
Neutropenia occurred in 21.8% of patients receiving asciminib, with grade 3 and 4 reactions reported in 7.6% and 6.3% of patients, respectively. Among the patients with neutropenia ≥ grade 3, the median time to first occurrence of reactions was 7.14 weeks (range: 0.14 to 180.14 weeks), with median duration of any occurring reaction of 1.86 weeks (95% CI, range: 1.29 to 2 weeks). 1.3% of patients receiving asciminib permanently discontinued due to neutropenia, while asciminib was temporarily withheld in 9.4% of patients due to the adverse reaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:31:00Z · SHA-256 a2fd46262678a8eeb46669611ee0714c6effd5303baddb16f404cbe6b0d0ab23 · Passage d84a576d239a786190bdbc7201c9f47beb6185b1308172ea84e1e8d24d595204 · Zeichen 9528–10081 im Abschnitt